Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 6/20 | 0.62 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CDA | P32320 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923936 | 0.84 | ADK (0.55) | ADK | |
| SCHEMBL13092037 | 0.76 | ADK (1.00) | ADKMAPT | |
| SCHEMBL16968468 | 0.76 | ADK (1.00) | ADKMAPT | |
| SCHEMBL16978217 | 0.76 | ADK (1.00) | ADKMAPT | |
| SCHEMBL18744585 | 0.76 | ADK (1.00) | ADKMAPT | |
| SCHEMBL23147965 | 0.76 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL22493077 | 0.76 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL20556173 | 0.76 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL28939188 | 0.76 | ADK (0.60) | ADKMAPTCDA | |
| SCHEMBL13621803 | 0.75 | SLC5A2 (0.71) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139484-A1 | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1803729-A1 | 1-( -D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-07-04 | — | — | EP | claimed |
| US-20080139484-A1 | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1803729-A1 | 1-( -D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139484-A1 | 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof | SLC5A1, SLC5A2, UGGT1 | ADK 2288/4885SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.